The Interpublic Group of Companies, Inc. (IPG)
NYSE: IPG · Real-Time Price · USD
24.24
-0.36 (-1.46%)
Aug 1, 2025, 4:00 PM - Market closed
Ligand Pharmaceuticals Stock Forecast
Stock Price Forecast
The 7 analysts that cover Ligand Pharmaceuticals stock have a consensus rating of "Buy" and an average price target of $31.59, which forecasts a 30.32% increase in the stock price over the next year. The lowest target is $25.6 and the highest is $35.
Price Target: $31.59 (+30.32%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Ligand Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Buy | 3 | 3 | 3 | 3 | 2 | 1 |
| Hold | 3 | 3 | 3 | 3 | 4 | 4 |
| Sell | 1 | 1 | 1 | 1 | 1 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 8 | 8 | 9 | 9 | 9 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Hold Maintains $27 → $26 | Hold | Maintains | $27 → $26 | +5.61% | Jul 23, 2025 |
| JP Morgan | JP Morgan | Buy Maintains $35 → $33 | Buy | Maintains | $35 → $33 | +36.14% | Jul 10, 2025 |
| Barclays | Barclays | Buy → Hold Downgrades $34 → $28 | Buy → Hold | Downgrades | $34 → $28 | +13.45% | Jun 25, 2025 |
| Barclays | Barclays | Buy Maintains $36 → $34 | Buy | Maintains | $36 → $34 | +40.26% | Apr 25, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $35 | Strong Buy | Initiates | $35 | +44.39% | Apr 15, 2025 |
Financial Forecast
Revenue This Year
8.89B
from 9.19B
Decreased by -3.21%
Revenue Next Year
9.15B
from 8.89B
Increased by 2.84%
EPS This Year
2.68
from 1.83
Increased by 46.51%
EPS Next Year
2.88
from 2.68
Increased by 7.25%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 9.3B | 9.6B | 9.9B | ||
| Avg | 8.9B | 9.1B | 9.4B | ||
| Low | 8.5B | 8.8B | 9.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.2% | 7.8% | 7.8% | ||
| Avg | -3.2% | 2.8% | 3.1% | ||
| Low | -7.5% | -1.1% | -1.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.87 | 3.10 | 3.39 |
| Avg | 2.68 | 2.88 | 3.07 |
| Low | 2.53 | 2.69 | 2.70 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 56.6% | 15.5% | 17.9% |
| Avg | 46.5% | 7.3% | 6.6% |
| Low | 38.2% | 0.1% | -5.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.